Patent foramen ovale closure is the standard treatment for cryptogenic stroke patients. However, there are is little information on its long-term evolution. The aim of this study was to determine clinical outcomes (death, ischemic or bleeding events) after foramen ovale closure over a 10-year evolution. The study included 201 consecutive patients (mean age 47…
CLOSE Trial: Patients with PFO with high flow or associated with interatrial septal aneurysm receiving closure device experience lower rates of recurrent stroke
Several cases have shown an association between patent foramen ovale and cryptogenic shock, particularly in patients under 55 and in those with atrial septal aneurysm or a significant right-to-left shunt. Using PFO closure for stroke prevention has been controversial and, so far, no randomized studies have shown the superiority of this strategy compared to anti-thrombotic…
Amplatzer and Figulla Devices Prove to Be Safe for Percutaneous Patent Foramen Ovale Closure
Courtesy of Dr. José Álvarez. In patients with presumed paradoxical embolism through a patent foramen ovale (PFO) who are at high risk of recurrent thromboembolic events, percutaneous PFO closure is an alternative to pharmacological treatment. This closure has been shown to be safe and feasible with different devices including various technologies based on an umbrella,…